NEW YORK, April 19 – In settling a suit with PerkinElmer Thursday, Genomic Solutions has paid PerkinElmer $5.5 million to buy back a large part of its stock, and given UK distribution rights to its products to PerkinElmer, but the settlement may make the company more attractive to investors, analysts are saying.

The settlement terminates PerkinElmer’s “call right” to shares of Genomic Solutions stock, which allowed PerkinElmer to call in all shares of Genomic Solutions and become the sole shareholder.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.